Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Padol
S
S
Yuan
Y
Y
Thabane
M
M
Padol
I T
IT
Hunt
R H
RH
D000897:Anti-Ulcer Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D065731:Cytochrome P-450 CYP2C19; D016480:Helicobacter pylori / Q000187:drug effects*; D006899:Mixed Function Oxygenases / Q000235:genetics* / Q000378:metabolism; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors
D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19